These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
663 related articles for article (PubMed ID: 28477403)
1. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer. Zhang L; Yao J; Li W; Zhang C Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403 [TBL] [Abstract][Full Text] [Related]
2. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Fang Y; Zhou W; Rong Y; Kuang T; Xu X; Wu W; Wang D; Lou W Exp Cell Res; 2019 Oct; 383(1):111543. PubMed ID: 31374207 [TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Wei L; Ye H; Li G; Lu Y; Zhou Q; Zheng S; Lin Q; Liu Y; Li Z; Chen R Cell Death Dis; 2018 Oct; 9(11):1065. PubMed ID: 30337520 [TBL] [Abstract][Full Text] [Related]
4. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329 [TBL] [Abstract][Full Text] [Related]
5. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325 [TBL] [Abstract][Full Text] [Related]
6. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK. Toste PA; Nguyen AH; Kadera BE; Duong M; Wu N; Gawlas I; Tran LM; Bikhchandani M; Li L; Patel SG; Dawson DW; Donahue TR Mol Cancer Res; 2016 May; 14(5):437-47. PubMed ID: 26979711 [TBL] [Abstract][Full Text] [Related]
8. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125 [TBL] [Abstract][Full Text] [Related]
10. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Hu C; Xia R; Zhang X; Li T; Ye Y; Li G; He R; Li Z; Lin Q; Zheng S; Chen R Mol Cancer; 2022 Jan; 21(1):24. PubMed ID: 35045883 [TBL] [Abstract][Full Text] [Related]
11. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296 [TBL] [Abstract][Full Text] [Related]
12. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840 [TBL] [Abstract][Full Text] [Related]
13. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer. Zhang X; Zhao P; Wang C; Xin B Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032 [TBL] [Abstract][Full Text] [Related]
14. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745 [TBL] [Abstract][Full Text] [Related]
15. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261 [TBL] [Abstract][Full Text] [Related]
17. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190 [TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Richards KE; Zeleniak AE; Fishel ML; Wu J; Littlepage LE; Hill R Oncogene; 2017 Mar; 36(13):1770-1778. PubMed ID: 27669441 [TBL] [Abstract][Full Text] [Related]
19. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Xiong G; Huang H; Feng M; Yang G; Zheng S; You L; Zheng L; Hu Y; Zhang T; Zhao Y J Exp Clin Cancer Res; 2018 Apr; 37(1):76. PubMed ID: 29615098 [TBL] [Abstract][Full Text] [Related]